Dystrophic Epidermolysis Bullosa Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Dystrophic Epidermolysis Bullosa market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Krystal Biotech, Inc., Anterogen Co., Ltd., Abeona Therapeutics, Inc, Phoenix Tissue Repair, Inc., RHEACELL GmbH & Co. KG, Scioderm, Inc., InMed Pharmaceuticals Inc.

[Nevada, United States] - DelveInsight's "Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Dystrophic Epidermolysis Bullosa, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Dystrophic Epidermolysis Bullosa Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Dystrophic Epidermolysis Bullosa Market Report:
• The Dystrophic Epidermolysis Bullosa market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In June, 2024: Abeona Therapeutics, Inc announced that To evaluate and further characterize the safety of EB-101 (LZRSE-Col7A1 gene-corrected keratinocyte sheets with type VII collagen [C7] expression) for the treatment of large, chronic RDEB wounds in new and previously EB-101 treated patients 12 months and older.
• In April, 2024: Castle Creek Biosciences, LLC. announced that the purpose of their study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa.
• In April, 2024: Anterogen Co., Ltd. announced that after confirming eligibility, a single subject with four selected target lesions will receive both ALLO-ASC-SHEET and Vehicle control, three target lesions for ALLO-ASC-SHEET and the other target for Vehicle control, and which lesion to apply which IP treatment will be determined randomly at the time of enrollment using pre-designed block randomization scheme.
• In April, 2024: Krystal Biotech, Inc. announced a 112-week (approximately two-year) open-label extension study of Beremagene Geperpavec (B-VEC), for participants aged 2 months and older, who have been diagnosed with Dystrophic Epidermolysis Bullosa (DEB). Participants will be dosed weekly with the topical B-VEC therapy.
• According to Stanford Medicine (2023), it is estimated that 25,000-50,000 people in the United States have epidermolysis bullosa.
• In France, according to the National higher education and research institute (2015), epidermolysis bullosa affects around 1 newborn in 20,000, which means around 30,000 cases in Europe and 500,000 worldwide, adults and children combined. There would be 700-800 children or young people affected in France.
• As per Eichstadt et. al. (2019), the prevalence ofDEB in the US is 3.26 per million and the prevalence of DEB in Spain is 6 per million.
• Key Dystrophic Epidermolysis Bullosa Companies are as follows: Krystal Biotech, Inc., Anterogen Co., Ltd., Abeona Therapeutics, Inc, Phoenix Tissue Repair, Inc., RHEACELL GmbH & Co. KG, Scioderm, Inc., InMed Pharmaceuticals Inc.
• Key Dystrophic Epidermolysis Bullosa Therapies are as follow: Topical Beremagene Geperpavec, ALLO-ASC-SHEET, EB-101, PTR-01, APZ2-EB, SD-101-6.0 cream, INM-755
• Launching multiple stage Dystrophic Epidermolysis Bullosa pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Dystrophic Epidermolysis Bullosa market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Dystrophic Epidermolysis Bullosa Overview:
Dystrophic epidermolysis bullosa (DEB) is the major subtypes of epidermolysis bullosa (EB). EB is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. EB is classified into four main types and several clinical subtypes.

Dystrophic Epidermolysis Bullosa Epidemiology Segmentation:
The Dystrophic Epidermolysis Bullosa market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Dystrophic Epidermolysis Bullosa Diagnosed Prevalent Cases
• Dystrophic Epidermolysis Bullosa Total Prevalent Cases
• Dystrophic Epidermolysis Bullosa Gender-specific Prevalence
• Dystrophic Epidermolysis Bullosa Type-specific Cases

For more information about Dystrophic Epidermolysis Bullosa companies working in the treatment market, visit https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Dystrophic Epidermolysis Bullosa Market Insights
Dystrophic Epidermolysis Bullosa (DEB) is a rare genetic disorder characterized by extreme fragility of the skin, causing blisters and wounds even with minor friction or trauma. It is one of the most severe forms of Epidermolysis Bullosa (EB) and significantly impacts patients' quality of life due to chronic wounds, infections, and a higher risk of skin cancer.

Dystrophic Epidermolysis Bullosa Drugs Uptake
• Beremagene Geperpavec (B-VEC): This gene therapy developed by Krystal Biotech is designed to deliver a functional copy of the COL7A1 gene directly into the patient's skin cells via a topical gel. It has shown promising results in clinical trials, offering hope for a disease-modifying treatment. B-VEC's market uptake is expected to increase significantly after regulatory approval.
• FCX-007 (Fibrocell Science): FCX-007 is an autologous cell-based gene therapy currently in clinical trials for RDEB. It involves genetically modifying the patient's fibroblasts to express the functional COL7 protein, which is critical for anchoring the layers of the skin.
• Rigosertib (Onconova Therapeutics): This drug, originally developed for cancer, is being investigated for its potential to inhibit pathways involved in the aggressive development of squamous cell carcinoma (SCC) in RDEB patients, as these patients are at a high risk of developing this fatal complication.
• Diacerein 1% Ointment (Castle Creek Pharmaceuticals): This topical treatment is being developed to reduce inflammation and improve wound healing in DEB patients.
• Oleogel-S10 (Birken AG): Oleogel-S10 is a topical treatment approved in Europe for wound healing in EB, including DEB. It works by improving wound closure and is expected to see increased adoption in markets where it has been approved.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Dystrophic Epidermolysis Bullosa Therapies and Key Companies:
• Topical Beremagene Geperpavec: Krystal Biotech, Inc.
• ALLO-ASC-SHEET: Anterogen Co., Ltd.
• EB-101: Abeona Therapeutics, Inc
• PTR-01: Phoenix Tissue Repair, Inc.
• APZ2-EB: RHEACELL GmbH & Co. KG
• SD-101-6.0 cream: Scioderm, Inc.
• INM-755: InMed Pharmaceuticals Inc.

Dystrophic Epidermolysis Bullosa Epidemiology:
Dystrophic Epidermolysis Bullosa is a rare condition, affecting approximately 6.5 to 10 per million live births globally. The incidence of DEB varies by region, with a higher prevalence in countries with consanguineous populations. DEB can be inherited in either a recessive (RDEB) or dominant (DDEB) manner, with RDEB being the more severe form. Patients with RDEB often experience extensive skin blistering, chronic wounds, and complications like squamous cell carcinoma, while DDEB tends to have a milder presentation.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Dystrophic Epidermolysis Bullosa Market Drivers:
• Increasing Awareness and Diagnosis
• Advancements in Gene Therapy and Regenerative Medicine
• Novel Wound Care and Skin Regeneration Therapies
• Increasing Research and Development Efforts

Dystrophic Epidermolysis Bullosa Market Barriers:
• High Cost of Gene and Cell Therapies
• Limited Market for Rare Disease Therapies
• Challenges in Diagnosis and Access to Care
• Complications and Comorbidities

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Dystrophic Epidermolysis Bullosa Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Dystrophic Epidermolysis Bullosa Companies: Krystal Biotech, Inc., Anterogen Co., Ltd., Abeona Therapeutics, Inc, Phoenix Tissue Repair, Inc., RHEACELL GmbH & Co. KG, Scioderm, Inc., InMed Pharmaceuticals Inc.
• Key Dystrophic Epidermolysis Bullosa Therapies: Topical Beremagene Geperpavec, ALLO-ASC-SHEET, EB-101, PTR-01, APZ2-EB, SD-101-6.0 cream, INM-755
• Dystrophic Epidermolysis Bullosa Therapeutic Assessment: Current marketed and emerging therapies
• Dystrophic Epidermolysis Bullosa Market Dynamics: Dystrophic Epidermolysis Bullosa Market drivers and Dystrophic Epidermolysis Bullosa barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dystrophic Epidermolysis Bullosa Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Dystrophic Epidermolysis Bullosa market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Dystrophic Epidermolysis Bullosa (DEB) Market Overview at a Glance
4. Executive Summary of Dystrophic Epidermolysis Bullosa (DEB)
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Background and Overview
8. Treatment and Management of DEB
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Drugs
12. Emerging Therapies
13. DEB: 7 Major Market Analysis
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.